apolipoprotein A-I Milano

variant of Apo-A-I characterized for a Cys for Arg substitution at position 173 of the amino acid sequence; causes abnormalities in the HDL fraction, high triglycerides & increased postprandial lipemia

Also Known As:

Networked: 31 relevant articles (3 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sirtori, Cesare R: 7 articles (04/2008 - 05/2002)
2.	Chiesa, Giulia: 5 articles (03/2008 - 05/2002)
3.	Shah, Prediman K: 3 articles (01/2016 - 08/2005)
4.	Sharifi, Behrooz G: 3 articles (01/2016 - 08/2005)
5.	Wang, Lai: 3 articles (01/2016 - 08/2005)
6.	Bisgaier, Charles L: 3 articles (04/2008 - 05/2002)
7.	Marchesi, Marta: 3 articles (04/2008 - 05/2002)
8.	Franceschini, Guido: 3 articles (11/2007 - 05/2002)
9.	De Geest, Bart: 2 articles (01/2020 - 03/2009)
10.	Nicholls, Stephen J: 2 articles (01/2018 - 03/2006)

Related Diseases

1.	Atherosclerosis 03/18/2008 - "Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis." 05/01/2005 - "Apolipoprotein A-I-Milano(AIM), a natural variant, not only inhibits the initiation and progression of atherosclerosis, but also makes the preexisting atherosclerotic lesions regress. " 04/01/2003 - "Furthermore, recombinant apolipoprotein A-I(Milano) has displayed remarkable atheroprotective activities and the possibility of directly reducing the burden of atherosclerosis in experimental models. " 01/01/2016 - "Apolipoprotein A-1 (Apo A-I) Milano, a naturally occurring Arg173to Cys mutant of Apo A-1, has been shown to reduce atherosclerosis in animal models and in a small phase 2 human trial. " 03/03/1998 - "In this study, we tested the hypothesis that apo A-I(Milano)/PC would inhibit aortic atherosclerosis in apo E-deficient mice. "
2.	Vascular Diseases (Vascular Disease) 05/17/2002 - "Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. " 04/01/2003 - "This review is aimed at providing an update on the experimental studies in which apolipoprotein A-I(Milano), produced as a recombinant protein, has displayed important effects in the treatment of vascular diseases. " 11/06/2007 - "Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant have very low plasma high-density lipoprotein cholesterol (HDL-C) levels but do not show any history of premature cardiovascular disease or any evidence of preclinical vascular disease. " 12/01/2005 - "No evidence of premature vascular disease is found in apolipoprotein A-I(Milano) (apoA-I(M)) human carriers, despite very low high density lipoprotein (HDL) cholesterol levels. "
3.	Coronary Disease (Coronary Heart Disease) 04/01/2003 - "The mutant apolipoprotein A-I(Milano) has been associated with a reduced incidence of coronary disease in carriers. " 02/23/2007 - "Carriers of the apolipoprotein A-I(Milano) (A-I(M)) variant present with severe reductions of plasma HDL levels, not associated with premature coronary heart disease (CHD). " 01/01/2018 - "Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial." 04/17/2001 - "Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant present with very low plasma HDL cholesterol and moderate hypertriglyceridemia, apparently not leading to premature coronary heart disease. "
4.	Acute Coronary Syndrome 01/01/2018 - "Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial." 01/01/2018 - "Infusing a high-density lipoprotein mimetic containing apolipoprotein A-I Milano demonstrated potential atheroma regression in patients following an acute coronary syndrome. " 08/01/2005 - "Recent evidence from a double-blind, randomized study showed that treatment with apolipoprotein A-I Milano (ApoA-I Milano) in a complex with phospholipids produced significant regression of the coronary atheroma burden in patients with acute coronary syndromes. "
5.	Atherosclerotic Plaque (Atheroma) 08/01/2010 - "Recombinant apolipoprotein A-I Milano (rApoA-I(M)) induces atherosclerotic plaque regression. " 03/01/2007 - "Synthetically produced recombined apolipoprotein A-I Milano administered intravenously seems to have a marked effect in reducing the atheroma burden. " 03/07/2006 - "Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano." 01/01/2003 - "Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques." 01/01/2018 - "Infusing a high-density lipoprotein mimetic containing apolipoprotein A-I Milano demonstrated potential atheroma regression in patients following an acute coronary syndrome. "

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	Apolipoproteins A
3.	Phospholipids (Phosphatides)
4.	Lipids
5.	Apolipoproteins
6.	HDL Lipoproteins
7.	Phosphatidylcholines (Phosphatidylcholine)
8.	Apolipoproteins E (ApoE)
9.	Recombinant Proteins
10.	ETC216

Related Therapies and Procedures

1.	Therapeutics
2.	Injections